IP Library Granted Patent US 8,673,877
Granted Patent B2
US 8,673,877 · App. 13/204,881 · Granted Mar 18, 2014

Use of lactulose in the treatment of autism

Inventors: Joan M. Fallon (Bronxville, NY); Richard Feltenstein (New Rochelle, NY)
Assignee: Curemark, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,877
App. No.
13/204,881
Granted
Mar 18, 2014
Kind
B2
Abstract

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Claims (12)

1. A method for decreasing levels of ammonia in an individual diagnosed with autism, comprising administering to the individual a therapeutically effective amount of lactulose and about 0.1 g/kg mannitol per dose, wherein administration of the lactulose follows administration of an antibiotic, and wherein administration of lactulose increases the number of lactobacilli and bifidobacteria in a gut flora.

2. The method of claim 1 , wherein the therapeutically effective amount of lactulose comprises about 0.4 g/kg lactulose per dose.

3. The method of claim 1 , wherein the therapeutically effective amount of lactulose comprises about 0.3 g/kg lactulose per dose.

4. The method of claim 1 , wherein the lactulose is administered approximately two to five times per day.

5. The method of claim 1 , wherein the lactulose is administered in a form selected from the group consisting of a powder, a liquid solution, a syrup, and a combination thereof.

6. The method of claim 5 , wherein the lactulose is administered in the form of a powder.

7. The method of claim 1 , wherein the level of ammonia is decreased in blood of the individual.

8. The method of claim 1 , wherein the level of ammonia is decreased in a gastrointestinal tract of the individual.

9. The method of claim 1 , wherein the level of ammonia is decreased in a nervous system of the individual.

10. The method of claim 1 , wherein the antibiotic is amoxicillin-clavulanate.

11. The method of claim 1 , wherein administration of the lactulose immediately follows administration of the antibiotic.

12. The method of claim 11 , wherein the antibiotic is amoxicillin-clavulanate.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE CUREMARK LLC PREVIOUSLY RECORDED ON REEL 026919 FRAME 0960. ASSIGNOR(S) HEREBY CONFIRMS THE FULL NAME OF THE ASSIGNEE HAS A COMMA. ASSIGNEE IS CUREMARK, LLC. Recorded Jan 18, 2017
From: FALLON, JOAN M.
To: CUREMARK, LLC
Reel/Frame 041392/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2011
From: FALLON, JOAN M.; FELTENSTEIN, RICHARD
To: CUREMARK LLC
Reel/Frame 026919/0960 →
Continuity (4)
Division 12049613 · Mar 17, 2008
Division 11468379 · Aug 30, 2006
Provisional Application 60712551 · Aug 30, 2005
Related Publication 20120004192A1 · Jan 5, 2012